The Graft Versus Host Disease (GVHD) drugs in development market research report provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Graft Versus Host Disease (GVHD). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued products.

GlobalData tracks 194 drugs in development for Graft Versus Host Disease (GVHD) by 176 companies/universities/institutes. The top development phase for Graft Versus Host Disease (GVHD) is preclinical with 82 drugs in that stage. The Graft Versus Host Disease (GVHD) pipeline has 174 drugs in development by companies and 20 by universities/ institutes. Some of the companies in the Graft Versus Host Disease (GVHD) pipeline products market are: Pfizer, H. Lee Moffitt Cancer Center & Research Institute and AnaptysBio.

The key targets in the Graft Versus Host Disease (GVHD) pipeline products market include Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2), Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2), and Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2).

The key mechanisms of action in the Graft Versus Host Disease (GVHD) pipeline product include Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Inhibitor with nine drugs in Filing rejected/Withdrawn. The Graft Versus Host Disease (GVHD) pipeline products include 14 routes of administration with the top ROA being Intravenous and 17 key molecule types in the Graft Versus Host Disease (GVHD) pipeline products market including Small Molecule, and Cell Therapy.

Graft Versus Host Disease (GVHD) overview

Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient’s body. Symptoms include abdominal pain or cramps; nausea, vomiting, and diarrhea; dry or irritated eyes; jaundice; shortness of breath; vaginal dryness; and weight loss. Treatment includes immunosuppressants.

For a complete picture of Graft Versus Host Disease (GVHD)’s pipeline drug market, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.